LAG525

Immutep Quarterly Activities Report

Retrieved on: 
Friday, April 29, 2022
ASCO, Public, Family, GMP, Time, Patent, Institute, FDA, Federal Service for Intellectual Property (Russia), Novartis, Paclitaxel, Cancer, Kinetics, Australian Securities Exchange, NASDAQ, Nivolumab, Phase, EMA, European Medicines Agency, Antibody, US Foods, Patient, GLOBE, Method, Central Statistics Office (India), Survival, Company, Intellectual property, LAG-3, LAG525, Infection, INN, HNSCC, Institutional review board, ASX, IMM, Technology, APC, Head, US, Autoimmune disease, Board, Carboplatin, Research and development, IKF, Annual general meeting, AIPAC, Development, Pembrolizumab, Russia, Friends, Society, MBC, Breast cancer, Cryptocurrency, Pharmaceutical industry, Vaccine, Research, NSCLC, Immutep

Immutep will report new biomarker and multivariate analysis data from the Phase IIb AIPAC trial in a poster presentation at ESMOs Breast Cancer Congress in May 2022.

Key Points: 
  • Immutep will report new biomarker and multivariate analysis data from the Phase IIb AIPAC trial in a poster presentation at ESMOs Breast Cancer Congress in May 2022.
  • In March 2022, Immutep received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical development program for efti in MBC.
  • The net cash used in G&A activities in the quarter was $1.6 million compared to $0.2 million in Q2 FY22.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

Retrieved on: 
Friday, March 18, 2022
Family, NASDAQ, Australian Securities Exchange, Patent, LAG-3, Cancer, Immutep, APC, Autoimmune disease, ASX, Immune system, Technology, Infection, IMM, LAG525, GLOBE, INN, Patient, Antibody, Pharmaceutical industry, Vaccine, Generic drug, Regulatory T cell, Novartis

7030750 entitled Antibody molecules to LAG-3 and uses thereof by the Japanese Patent Office.

Key Points: 
  • 7030750 entitled Antibody molecules to LAG-3 and uses thereof by the Japanese Patent Office.
  • This new Japanese patent was filed as a divisional application and follows the grant of the parent Japanese patent announced in 2019.
  • The compositions may also be administered in combination with a second agent such as an anti-PD-1 antibody, an anti-PD-L1 antibody or a chemotherapeutic agent.
  • IMP701 is a therapeutic antagonist antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

Retrieved on: 
Friday, August 27, 2021
Cancer, LAG525, Infection, Immune system, GLOBE, INN, Chinese patent medicine, Novartis, LAG-3, Antibody, NASDAQ, ASX, Immutep, Patent, Pharmaceutical industry, Vaccine, Generic drug

ZL201580013695.X entitled Antibody molecules to LAG-3 and uses thereof by the Chinese Patent Office.

Key Points: 
  • ZL201580013695.X entitled Antibody molecules to LAG-3 and uses thereof by the Chinese Patent Office.
  • This new Chinese patent follows the grant of the corresponding Australian, United States, European, and Japanese patents announced in 2018 through 2020.
  • LAG525 (INN: leramilimab) is a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
  • IMP701 is a therapeutic antagonist antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

Immutep Announces United States Patent Grant for IMP701 Antibody

Retrieved on: 
Wednesday, July 15, 2020
Medical specialties, Medicine, Health, Monoclonal antibodies, Immunology, Immutep, LAG3, Novartis, LAG525, Antibody, Monoclonal antibody therapy

SYDNEY, Australia, July 15, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) announces the grant of patent no.

Key Points: 
  • SYDNEY, Australia, July 15, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) announces the grant of patent no.
  • 10,711,060 entitled Antibody molecules to LAG-3 and uses thereof by the United States Patent and Trade Mark Office.
  • This new United States patent is directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
  • IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

Retrieved on: 
Tuesday, June 30, 2020
Organ systems, Medical specialties, Medicine, Immune system, Monoclonal antibodies, Immune checkpoint, Neuroblastoma, Cancer treatments, LAG525

Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

Key Points: 
  • Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma.
  • We are very grateful to all clinical sites involved in developing omburtamab, and especially to our employees in the development team.
  • Dr. Claus Moller, Chief Executive Officer, continued, We look forward to working with the Agency to bring omburtamab to appropriate patients.

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma

Retrieved on: 
Thursday, April 30, 2020
Medicine, Clinical medicine, Cancer, Immune system, Nasopharynx cancer, Pharynx, Monoclonal antibody, Durvalumab, LAG525

The sNDA is the worlds first new drug application of anti-PD-1 monoclonal antibody for the treatment of recurrent/metastatic nasopharyngeal carcinoma.

Key Points: 
  • The sNDA is the worlds first new drug application of anti-PD-1 monoclonal antibody for the treatment of recurrent/metastatic nasopharyngeal carcinoma.
  • We believe toripalimab has the potential to meet the urgent need for safe and effective treatments in more advanced recurrent and metastasized NPC patients.
  • We have now completed POLARIS-02, the Phase II clinical study in NPC patients who have failed first line systemic therapy.
  • The study is the worlds first large clinical trial of anti-PD-1 monoclonal antibody for the treatment of advanced nasopharyngeal carcinoma enrolling 190 patients.

Immutep Announces European Patent Grant for LAG525 Antibody

Retrieved on: 
Thursday, November 14, 2019
Immutep, Medicine, Medical specialties, Monoclonal antibodies, Clinical medicine, LAG3, Antibody, LAG525, Eftilagimod alpha

SYDNEY, Australia, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company) is pleased to announce the grant of patent no.

Key Points: 
  • SYDNEY, Australia, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company) is pleased to announce the grant of patent no.
  • 3116909 entitled Antibody molecules to LAG-3 and uses thereof by the European Patent Office.
  • The claims of the patent are directed to LAG525, and to the use of LAG525 in the treatment of cancer and infectious disease.
  • LAG525 is a humanised form of Immuteps IMP701 antibody that was originally developed by Immutep S.A. (now Immutep S.A.S.

Immutep Announces Japanese Patent Grant for LAG525 Antibody

Retrieved on: 
Tuesday, September 17, 2019
Immutep, Medicine, Medical specialties, Monoclonal antibodies, Clinical medicine, LAG3, Antibody, LAG525, Eftilagimod alpha

SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company) is pleased to announce the grant of patent no.

Key Points: 
  • SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company) is pleased to announce the grant of patent no.
  • 6576962 entitled Antibody molecules to LAG-3 and uses thereof by the Japanese Patent Office.
  • The claims of the patent are directed to LAG525, and to the use of LAG525 in the treatment of cancer and infectious disease.
  • LAG525 is a humanised form of Immuteps IMP701 antibody that was originally developed by Immutep S.A. (now Immutep S.A.S.